The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance
Guang Yang(Harvard University), Steven P. Treon(Harvard University)
Cited by 28
Related Papers
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
|Blood Cancer Journal|2020|44